Activation of Phospholipase C beta by G Proteins
G 蛋白激活磷脂酶 C beta
基本信息
- 批准号:7878896
- 负责人:
- 金额:$ 18.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-10 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylcholineAgonistBeliefBindingBiochemicalCalciumCalcium SignalingCatalysisCatalytic DomainCellsComplexDrug Delivery SystemsEnzyme ActivationEnzymesFluorescenceFundingGTP-Binding ProteinsHeterotrimeric GTP-Binding ProteinsHormonesHydrolysisIonsLifeLightLipidsMembraneMethodsModelingMolecularNeurotransmittersPH DomainPathway interactionsPharmacologic SubstancePhosphatidylinositolsPhospholipase CProtein Kinase CProtein SubunitsProteinsRegulationSecond Messenger SystemsSignal TransductionSiteStructural ModelsStructureSurfaceSystemTestingWorkbasecell growthdesignextracellularphospholipase C betaprotein activationprotein complexreceptorresponsesecond messenger
项目摘要
Heterotrimeric G proteins are activated by membrane receptors that respond to a diverse set of agonists
ranging from hormones, ions, light and neurotransmitters. Activated G proteins in turn can activate a host
of intracellular effector proteins, one of which is phospholipase C-beta (PLCb). PLCb catalyzes the
hydrolysis of the signaling lipid phosphatidylinositol 4,5 bisphosphate to release two second messengers
that cause an increase in intracellular calcium and activation of protein kinase C. The mechanism through
which G proteins activate PLCb or other effectors is unknown mainly due to a lack of structural information
about PLCb - G protein complexes. PLCb is a multidomain enzyme and we have found that Gbetagamma
subunits bind to one of these domains confering activation to the catalytic core. InAim 1we will determine
the mechanism through which activator binding changes interdomain contacts that allow for increased
catalysis. We have also found that catalysis can be increased to different and distinct levels depending on
the activation conditions opening up the possibility that activation of PLCb can befine-tuned to elicit
particular cellular responses. This idea will be tested in Aim 2. Activation of PLCb by Gbetagamma subunits
is long-lived but can be significantly reduced by changing PLCb-Gbetagammathrough the presence of
another protein partner such as Galpha(GDP). This mechanism will be investigated both biophysically and
in living cells in Aim 3. Inthe previous funding period, we have found that PLCb will bind to and inhibit the
very robust enzyme PLCdelta, and that release of Gbetagamma subunits during signaling will displace
PLCb from the complex allowing for both activation of PLCb and reversal of PLCd inhibition. In Aim 4 we
will better define the ability of these two PLCs to regulate calcium signals in cells.
Activation of PLCbeta by G proteins causes an increase in the cellular levels of calcium that in turn
activates a variety of proteins leading changes in cell growth and division. PLCb - G protein activation is
key cellular response for agents such as acetylcholine and a large number of pharmaceutical agents. This
proposal seeks to understand on the molecular level howthis activation occurs with the belief that
understanding this system on a basic level will allow for the design of more effective and targeted drugs.
异源三聚体G蛋白被膜受体激活,这些受体对不同的激动剂有反应
包括激素、离子、光和神经递质。激活的G蛋白反过来可以激活宿主
细胞内效应蛋白,其中之一是磷脂酶C-β(PLCb)。PLCb催化
水解信号脂质磷脂酰肌醇4,5二磷酸以释放两个第二信使
导致细胞内钙离子增加和蛋白激酶C激活。有何机制
主要由于缺乏结构信息,G蛋白激活PLCb或其他效应物是未知的
关于PLCb-G蛋白复合物。PLCb是一种多结构域酶,我们发现,
亚基与这些结构域之一结合,赋予催化核心活化。在目标1中,我们将确定
激活剂结合改变域间接触的机制,
催化作用我们还发现,催化作用可以增加到不同的和不同的水平,这取决于
激活条件开启了PLCb激活可以被微调以引发
特殊的细胞反应。这一想法将在目标2中得到检验。通过G β γ亚单位激活PLC b
是长期存在的,但可以通过改变PLCb-β-γ通过存在显着减少
另一种蛋白质伴侣,如Galalpha(GDP)。这一机制将在生物药理学和
在Aim 3的活细胞中。在上一个资助期内,我们发现PLCb会约束和抑制
非常强大的酶PLC δ,并且在信号传导过程中释放的γ亚基将取代
从复合物中释放PLCb,允许PLCb的激活和PLCd抑制的逆转。在目标4中,
将更好地定义这两种PLC调节细胞中钙信号的能力。
G蛋白激活PLC β导致细胞内钙水平升高,
激活多种蛋白质,导致细胞生长和分裂的变化。PLCb-G蛋白激活是
对于诸如乙酰胆碱和大量药剂的药剂的关键细胞应答。这
该提案试图在分子水平上理解这种激活是如何发生的,
在基本水平上理解这一系统将允许设计更有效和更有针对性的药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suzanne F Scarlata其他文献
Suzanne F Scarlata的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suzanne F Scarlata', 18)}}的其他基金
UNDERSTANDING RECEPTOR AND G PROTEIN INTERACTIONS IN LIVE CELLS
了解活细胞中受体和 G 蛋白的相互作用
- 批准号:
7956560 - 财政年份:2009
- 资助金额:
$ 18.23万 - 项目类别:
UNDERSTANDING RECEPTOR AND G PROTEIN INTERACTIONS IN LIVE CELLS
了解活细胞中受体和 G 蛋白的相互作用
- 批准号:
7724074 - 财政年份:2008
- 资助金额:
$ 18.23万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 18.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 18.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 18.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)